公司資料
GeoVax Labs 股價、新聞與催化劑
- 股票代碼:
- GOVX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.32 USD (-3.56%)
收盤價
最後更新: 2026年10月1日
10.9M USD
市值
股價為何變動
截至 2026年10月1日，GOVX 下跌 3.56%，收於 $0.3222。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Vaccine and Immunotherapy Company
GeoVax Labs develops vaccines and cancer immunotherapies using modified vaccinia Ankara vectors and gene-directed therapy. Its portfolio targets emerging infectious diseases and difficult-to-treat solid tumors.
GEO-MVA for Mpox and Smallpox
GEO-MVA is a live, non-replicating MVA vaccine being developed for protection against mpox and smallpox. The program is intended to support public-health preparedness and provide an alternative vaccine option for vulnerable populations.
Immunobridging Regulatory Strategy
Because efficacy trials against smallpox are not feasible, GeoVax plans to compare immune responses generated by GEO-MVA with those from an established vaccine. A successful immunobridging study could support regulatory submissions.
Gedeptin Cancer Gene Therapy
Gedeptin is a gene-directed enzyme prodrug therapy delivered into tumors. It is designed to convert an administered prodrug into an active anticancer agent locally and is being explored with checkpoint inhibition.
MVA Platform Capabilities
The company's MVA technology can deliver multiple antigens in a single vaccine and stimulate both antibody and T-cell responses. Government relationships and external manufacturing partners are important to development and stockpile opportunities.
未來催化劑
- Initiation of the pivotal GEO-MVA immunobridging study in the fourth quarter of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。